Penumbra logo
Penumbra PEN
$ 337.13 0.26%

Annual report 2025
added 02-25-2026

report update icon

Penumbra Financial Ratios 2011-2026 | PEN

Annual Financial Ratios Penumbra

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

74.3 744.0 110.8 -4942.7 1542.8 -647.9 127.7 739.2 717.7 145.8 217.0 6.1 - - -

P/S

9.4 8.7 9.5 11.7 10.9 18.2 11.3 11.0 10.0 8.2 2.8 0.1 - - -

EPS

4.6 0.4 2.4 -0.1 0.1 -0.4 1.4 0.2 0.1 0.5 0.1 -0.2 0.2 - -

EV (Enterprise Value)

13.4 B 10.5 B 10.3 B 10.2 B 8.38 B 10.3 B 6.3 B 4.9 B 3.37 B 2.19 B 525 M 144 M 75.1 M - -

EBITDA per Share

5.31 0.85 2.63 0.8 0.24 -0.73 1.6 1.06 0.15 0.0311 0.495 0.166 - - -

EV/EBITDA

938.1 -363.6 110.0 133.1 665.5 2266.8 83.3 2.7 - - -

PEG

0.47 32.09 2.36 -40.38 10.13 -4.05 0.2 20.7 -10.05 0.33 -21.7 0.03 - - -

P/B

9.3 9.1 8.5 9.9 8.5 16.0 12.7 11.6 8.3 8.1 2.2 -1.1 - - -

P/CF

55.3 61.9 103.6 -177.8 857.9 -306.0 1362.6 254.1 -1427.7 -81.7 -18.5 -1.3 - - -

ROE %

12.45 1.22 7.71 -0.20 0.55 -2.46 9.97 1.56 1.16 5.56 1.02 -18.15 - - -

ROA %

9.73 0.91 5.84 -0.15 0.42 -1.91 7.28 1.28 0.98 4.81 0.90 1.85 - - -

ROCE %

13.26 0.81 6.24 0.61 -0.79 -6.11 8.26 6.68 0.27 -0.50 1.77 2.99 - - -

Current Ratio

4.6 4.0 4.1 3.7 4.3 4.4 5.1 6.2 7.4 7.4 8.7 5.5 - - -

DSO

46.5 56.4 69.9 72.7 60.7 71.8 70.6 67.2 63.4 66.4 58.9 59.8 - - -

DIO

331.7 329.9 350.6 349.6 323.8 305.9 318.3 277.2 297.0 288.1 334.0 286.2 - - -

DPO

26.1 24.3 26.1 23.5 18.5 24.0 31.4 19.6 21.1 16.2 15.1 20.1 - - -

Operating Cycle

378.2 386.4 420.4 422.3 384.5 377.7 388.9 344.4 360.5 354.5 392.9 346.0 - - -

Cash Conversion Cycle

352.1 362.1 394.3 398.8 366.1 353.7 357.5 324.8 339.3 338.3 377.8 325.9 - - -

All numbers in USD currency

Quarterly Financial Ratios Penumbra

2025-Q3 2025-Q2 2025-Q1 2024-Q3 2024-Q2 2024-Q1 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

1.17 1.17 1.02 0.76 -1.55 0.28 0.24 0.49 0.22 - -0.06 -0.1 - -0.66 0.24 0.25 0.32 0.1 -0.24 -0.34 0.04 0.28 0.33 0.48 0.31 0.19 -0.55 0.39 0.16 0.27 0.01 -0.05 -0.1 -0.08 0.39 0.1 0.08 0.05 0.04 -0.11 0.1 0.02 -0.25 0.02 0.06 - - - - - - - - - - - -

EBITDA per Share

1.25 1.06 1.18 0.92 -2.02 0.51 0.39 0.53 0.38 - 0.21 0.05 0.04 - 0.53 0.29 0.46 - -0.3 -0.33 0.1 - 0.54 0.48 0.38 - -0.48 0.36 0.16 - 0.1 - -0.04 - -0.02 - 0.08 - 0.34 -0.67 0.88 - 0.11 - - - - - - - - - - - - - -

ROE %

12.78 4.22 1.64 -0.76 -1.66 4.36 3.21 2.15 -0.01 -0.61 -3.19 -1.66 -0.05 1.62 4.77 2.11 -0.99 -2.45 -1.02 2.72 7.99 9.97 9.56 2.71 2.46 1.56 2.25 6.80 3.24 1.16 -2.00 2.40 3.92 5.56 7.16 3.08 0.80 1.02 -3.05 -4.83 -3.68 -4.75 -1.39 - - - - - - - - - - - - - -

ROA %

9.79 3.24 1.23 -0.60 -1.28 3.26 2.39 1.59 0.28 -0.16 -2.14 -1.06 0.24 1.53 3.95 0.67 -0.78 -1.91 -0.90 1.90 5.84 7.28 7.12 1.71 1.82 1.28 1.89 5.62 2.69 0.98 -1.71 2.11 3.41 4.81 6.20 2.68 0.69 0.90 0.62 0.42 1.43 0.48 0.14 - - - - - - - - - - - - - -

ROCE %

13.28 2.71 0.56 -1.62 -3.15 4.61 4.16 3.58 1.88 0.12 1.40 2.13 3.67 4.88 1.74 -2.68 -6.97 -5.80 -3.13 2.68 8.07 7.60 2.66 -4.95 -5.38 -1.78 -1.61 3.50 0.97 -0.67 -1.18 -1.87 -1.79 -0.07 0.86 2.31 0.93 1.01 -1.50 -4.95 -3.31 -2.51 -2.51 - - - - - - - - - - - - - -

Current Ratio

4.5 4.4 4.2 4.0 4.1 4.2 4.0 3.9 3.8 3.7 3.8 - 3.8 4.3 3.4 - 4.4 4.4 4.4 4.4 4.4 3.7 3.7 3.7 3.7 5.6 5.6 5.6 5.6 6.2 6.2 6.2 6.2 7.4 7.4 7.4 7.4 8.4 8.4 8.4 8.4 5.5 5.5 - - - - - - - - - - - - - -

DSO

46.2 46.2 48.4 57.1 59.9 65.3 70.0 72.6 77.6 - 40.4 31.4 62.1 56.8 28.8 31.3 65.0 62.7 69.2 99.5 73.3 66.5 69.3 72.0 66.7 61.3 63.0 57.9 54.7 55.1 63.1 65.7 63.1 54.1 58.9 60.7 57.3 49.4 53.3 63.5 56.6 48.8 26.6 - - - - - - - - - - - - - -

DIO

343.4 333.4 341.1 347.5 258.0 361.5 358.7 338.8 342.5 - 186.5 168.4 320.9 303.0 333.6 348.1 366.5 276.0 333.0 498.6 344.6 296.2 320.9 346.6 275.4 251.0 287.0 282.5 265.9 267.9 297.2 292.0 300.4 251.2 274.0 281.9 328.7 288.4 306.1 346.8 336.7 265.1 130.8 - - - - - - - - - - - - - -

DPO

23.1 23.4 27.1 29.9 21.8 28.3 26.3 26.0 27.7 - 14.8 8.7 16.4 15.7 8.9 10.7 23.3 17.7 21.4 32.0 27.0 29.2 31.7 34.2 23.9 17.7 20.3 20.0 18.9 19.1 21.2 20.8 19.4 14.1 15.4 15.9 16.9 13.0 13.8 15.7 18.3 18.6 9.2 - - - - - - - - - - - - - -

Operating Cycle

389.6 379.5 389.5 404.6 317.8 426.7 428.7 411.5 420.1 - 226.9 199.9 382.9 359.9 362.4 379.4 431.5 338.6 402.2 598.1 417.9 362.7 390.2 418.7 342.1 312.3 350.1 340.4 320.6 323.0 360.3 357.6 363.5 305.3 332.9 342.6 386.0 337.8 359.4 410.3 393.4 313.9 157.4 - - - - - - - - - - - - - -

Cash Conversion Cycle

366.4 356.1 362.4 374.7 296.0 398.5 402.4 385.4 392.4 - 212.1 191.2 366.5 344.1 353.5 368.7 408.2 320.9 380.8 566.0 390.8 333.4 358.5 384.4 318.2 294.6 329.8 320.4 301.7 303.9 339.2 336.9 344.1 291.1 317.4 326.7 369.1 324.8 345.6 394.6 375.0 295.3 148.2 - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Penumbra, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Sensus Healthcare Sensus Healthcare
SRTS
$ 4.1 -2.96 % $ 66.9 M usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
Aziyo Biologics Aziyo Biologics
AZYO
- 1.37 % $ 20.5 M usaUSA
Acutus Medical Acutus Medical
AFIB
- -26.83 % $ 2.62 M usaUSA
Integra LifeSciences Holdings Corporation Integra LifeSciences Holdings Corporation
IART
$ 9.86 3.25 % $ 759 M usaUSA
BioSig Technologies BioSig Technologies
BSGM
- 37.08 % $ 85.7 M usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
Delcath Systems Delcath Systems
DCTH
$ 9.18 -0.22 % $ 329 M usaUSA
Stryker Corporation Stryker Corporation
SYK
$ 335.31 2.37 % $ 128 B usaUSA
Dynatronics Corporation Dynatronics Corporation
DYNT
- 14.99 % $ 929 K usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
Second Sight Medical Products Second Sight Medical Products
EYES
- -0.97 % $ 54.4 M usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
TELA Bio TELA Bio
TELA
$ 0.71 3.13 % $ 33.3 M usaUSA
CryoLife, Inc. CryoLife, Inc.
CRY
- -4.14 % $ 702 M usaUSA
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
- 1.15 % $ 34.5 M usaUSA
CONMED Corporation CONMED Corporation
CNMD
$ 36.91 -0.32 % $ 1.15 B usaUSA
Insulet Corporation Insulet Corporation
PODD
$ 220.63 2.14 % $ 15.5 B usaUSA
Soliton, Inc. Soliton, Inc.
SOLY
- -1.42 % $ 435 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
- 0.03 % $ 1.58 B israelIsrael
Tandem Diabetes Care Tandem Diabetes Care
TNDM
$ 23.46 -3.32 % $ 1.6 B usaUSA
Electromed Electromed
ELMD
$ 24.74 0.32 % $ 209 M usaUSA
Misonix, Inc. Misonix, Inc.
MSON
- - $ 462 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
- - $ 955 M usaUSA
Cytosorbents Corporation Cytosorbents Corporation
CTSO
$ 0.62 -8.39 % $ 33.7 M usaUSA
Aethlon Medical Aethlon Medical
AEMD
$ 2.37 2.22 % $ 3.7 M usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
Smith & Nephew plc Smith & Nephew plc
SNN
$ 32.45 - $ 23.8 B britainBritain
LivaNova PLC LivaNova PLC
LIVN
$ 64.75 2.28 % $ 3.53 B britainBritain
InspireMD InspireMD
NSPR
$ 1.74 -0.57 % $ 112 M israelIsrael
AdaptHealth Corp. AdaptHealth Corp.
AHCO
$ 11.6 1.84 % $ 1.57 B usaUSA
MiMedx Group MiMedx Group
MDXG
$ 4.08 -0.49 % $ 603 M usaUSA
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
Viemed Healthcare Viemed Healthcare
VMD
$ 9.32 -0.32 % $ 363 M usaUSA
Myomo Myomo
MYO
$ 0.69 -1.61 % $ 28.9 M usaUSA
NanoVibronix NanoVibronix
NAOV
- - $ 1.08 M usaUSA
Varex Imaging Corporation Varex Imaging Corporation
VREX
$ 10.72 0.28 % $ 444 M usaUSA
Vivos Therapeutics Vivos Therapeutics
VVOS
$ 1.24 7.37 % $ 6.22 M usaUSA
Inspire Medical Systems Inspire Medical Systems
INSP
$ 51.41 - $ 1.51 B usaUSA
Pulmonx Corporation Pulmonx Corporation
LUNG
$ 1.29 -1.15 % $ 52.5 M usaUSA
Beyond Air Beyond Air
XAIR
$ 0.74 0.01 % $ 50.1 M usaUSA
Xtant Medical Holdings Xtant Medical Holdings
XTNT
$ 0.57 0.85 % $ 76.2 M usaUSA